Active, not recruitingPhase 3NCT05680818
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Studying Autosomal dominant hypocalcemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Principal Investigator
- Calcilytix Medical DirectorCalcilytix Therapeutics, Inc., a BridgeBio company
- Intervention
- Encaleret(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2023 – 2029
Study locations (25)
- UCSF Benioff Children's Hospital, Oakland, Oakland, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Indiana University Health University Hospital, Indianapolis, Indiana, United States
- NIH, Bethesda, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Physicians East, Greenville, North Carolina, United States
- Ohio State University Medical Center, Columbus, Ohio, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Houston Methodist Hospital, Houston, Texas, United States
- Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
- Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
- Bone Research & Education Centre, Oakville, Ontario, Canada
- Vseobecna fakultni nemocnice v Praze, New Town, Czechia
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05680818 on ClinicalTrials.govOther trials for Autosomal dominant hypocalcemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07428057Postoperative Hypocalcemia After ThyroidectomyMinia University
- RECRUITINGPHASE2, PHASE3NCT07080385Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)Calcilytix Therapeutics, Inc., a BridgeBio company
- ACTIVE NOT RECRUITINGNCT05227287ADH1 and ADH2 Disease Monitoring Study (DMS)Calcilytix Therapeutics, Inc., a BridgeBio company